Predict your next investment

Government
nimh.nih.gov

See what CB Insights has to offer

Investments

25

Portfolio Exits

4

Partners & Customers

5

About National Institute of Mental Health

The National Institute of Mental Health (NIMH) is part of the federal government of the United States and the largest research organization in the world specializing in mental illness. NIMH is particularly known for studies of genetics, neuroscience, and clinical trials of psychiatric medication.

National Institute of Mental Health Headquarter Location

6001 Executive Boulevard

North Bethesda, Maryland, 20852,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest National Institute of Mental Health News

Valera Health Secures $15M Led by Windham Venture Partners to Expand the Company’s Mental Health Clinical Services Across the U.S.

Jan 12, 2022

NEW YORK, Nov. 4, 2021 /PRNewswire/ — Valera Health announced today the closing of an oversubscribed $15M funding round led by Windham Venture Partners with participation from new investors Aquiline Technology Growth, MultiCare Health System, Divergent Investments, Watershed, GreyMatter Capital and Gaingels. Existing investors including AXA Venture Partners, Figure Eight Investments, Alsora Capital, Startup Health and Dr. Tom Insel, former Director of National Institute of Mental Health, also participated. This financing follows Valera’s expansion from a technology platform company to a fully integrated, tech-enabled, clinical services platform in the summer of 2020. Valera Health provides tech-driven virtual mental health services to patients with high acuity conditions, including serious mental illness (SMI) and severe depression. The company offers personalized services to everyone in need of mental health care, including those in rural and urban communities, BIPOC and LGBTQ+ communities with culturally intentional care and a diverse, multilingual provider network. Valera’s emphasis on measurement-based care and evidence-based treatments delivers improved quality scores for health plans. Over the past twelve months, Valera has partnered with health plans and provider groups that cover over 12 million lives and will be expanding to multiple states in the coming months. With a team-based care model that includes licensed therapists, nurse practitioners, case managers, and psychiatrists, Valera Health breaks down barriers of accessibility and prioritizes patients’ mental health by concentrating on outcomes and utilizing value-based models. “The pandemic exacerbated the mental health challenges we are facing. With declining stigma and greater focus on mental health issues, the demand for good therapists and psychiatrists is at an all-time high and growing rapidly” said Windham General Partner Adam Fine. “Valera Health is making an immediate impact and seeing 30%+ month-over-month growth because the company delivers excellent outcomes and helps patients feel better. We are excited to partner with Tom and his team”. “We’re honored to have forward-looking partners who recognize the critical need for Valera’s services and our commitment to serving patients who have been neglected historically. This financing will fuel our growth as we partner with leading health systems and health plans to make quality mental health care accessible for those with serious and persistent mental illness,” said Dr. Thomas Tsang, co-founder and CEO of Valera. About Valera Health: Valera Health is a high performing mental health company providing comprehensive longitudinal service using a team-based care model of coaches, therapists and medication prescribers augmented by proprietary digital technology and analytics. From meditation to therapy to medications, patients with mild depression to severe schizophrenia are treated with expert care. A focus on quality has achieved high HEDIS scores and produced significant outcomes. For more information go to:   www.valerahealth.com . Media Contact:  Tucker Stevenson,   tucker.stevenson@valerahealth.com About Windham Venture Partners: Windham is a NYC-based venture capital firm focused on healthtech. Windham partners with exceptional entrepreneurs and companies that are developing game-changing technologies to serve unmet needs, improve outcomes and help the lives of large numbers of patients. Windham is led by seasoned healthcare industry executives, operators and investors. SOURCE Valera Health

National Institute of Mental Health Investments

25 Investments

National Institute of Mental Health has made 25 investments. Their latest investment was in Camino Pharma as part of their Grant - II on June 6, 2020.

CBI Logo

National Institute of Mental Health Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

6/30/2020

Grant - II

Camino Pharma

$0.92M

Yes

1

5/19/2020

Grant - V

University of Illinois at Chicago

$5.9M

Yes

1

9/20/2019

Grant - V

Feinstein Institute for Medical Research

$7.3M

Yes

1

9/19/2019

Grant - II

Subscribe to see more

$99M

Subscribe to see more

10

11/19/2018

Grant

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/30/2020

5/19/2020

9/20/2019

9/19/2019

11/19/2018

Round

Grant - II

Grant - V

Grant - V

Grant - II

Grant

Company

Camino Pharma

University of Illinois at Chicago

Feinstein Institute for Medical Research

Subscribe to see more

Subscribe to see more

Amount

$0.92M

$5.9M

$7.3M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

1

1

10

10

National Institute of Mental Health Portfolio Exits

4 Portfolio Exits

National Institute of Mental Health has 4 portfolio exits. Their latest portfolio exit was Tridiuum on January 17, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

1/17/2022

Acquired

1

5/26/2020

Acquired

Subscribe to see more

Subscribe to see more

10

8/29/2018

Acquired

Subscribe to see more

Subscribe to see more

10

3/31/2009

Asset Sale

Subscribe to see more

Subscribe to see more

10

Date

1/17/2022

5/26/2020

8/29/2018

3/31/2009

Exit

Acquired

Acquired

Acquired

Asset Sale

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

10

National Institute of Mental Health Partners & Customers

5 Partners and customers

National Institute of Mental Health has 5 strategic partners and customers. National Institute of Mental Health recently partnered with PsychoGenics on March 3, 2018.

Date

Type

Business Partner

Country

News Snippet

Sources

3/15/2018

Licensee

PsychoGenics

United States

PsychoGenics Obtains License to the TgF344-AD Rat Model of Alzheimer’s Disease

PARAMUS , N.J. -- -- PsychoGenics Inc. announced today that it obtained a license from the National Institute of Mental Health , part of the National Institutes of Health , to the TgF344-AD rat model of Alzheimer 's disease .

1

7/13/2015

Partner

Foundation for the National Institutes of Health

United States

Subscribe to see more

Subscribe to see more

10

9/16/2013

Partner

U.S. Army

United States

Subscribe to see more

Subscribe to see more

10

10/5/2009

Vendor

SRI International

United States

Subscribe to see more

Subscribe to see more

10

Vendor

SysAid Technologies

Israel

Subscribe to see more

Subscribe to see more

10

Date

3/15/2018

7/13/2015

9/16/2013

10/5/2009

Type

Licensee

Partner

Partner

Vendor

Vendor

Business Partner

PsychoGenics

Foundation for the National Institutes of Health

U.S. Army

SRI International

SysAid Technologies

Country

United States

United States

United States

United States

Israel

News Snippet

PsychoGenics Obtains License to the TgF344-AD Rat Model of Alzheimer’s Disease

PARAMUS , N.J. -- -- PsychoGenics Inc. announced today that it obtained a license from the National Institute of Mental Health , part of the National Institutes of Health , to the TgF344-AD rat model of Alzheimer 's disease .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

10

10

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.